New Cancer Shot Amivantamab Shows Promise in Tumor Eradication for Resistant Patients
A new cancer treatment, an injection called amivantamab, has shown promising results in a clinical trial involving 102 patients with head and neck cancer. The trial, which spanned 11 countries, revealed that over one-third of the participants experienced a reduction in tumor size. Specifically, 28 patients saw significant tumor shrinkage, while 15 patients had their tumors dissolve completely. The treatment was particularly offered to patients whose cancer was resistant to other treatments or had recurred. The injection works by targeting cancer in three ways: blocking epidermal growth factor receptors, inhibiting the MET pathway, and activating the immune system to attack tumors. Developed by Johnson & Johnson, amivantamab is currently being evaluated in 60 medical trials for various cancers, including lung, colorectal, brain, and gastric cancer. 
